



COUNTY OF LOS ANGELES

Public Health

JONATHAN E. FIELDING, M.D., M.P.H.
Director and Health Officer

JONATHAN E. FREEDMAN
Chief Deputy

Alcohol and Drug Program Administration

WAYNE K. SUGITA, M.P.A.

Acting Director

1000 South Fremont Avenue

Building A-9 East, Third Floor

Alhambra, CA 91803

TEL (626) 299-4193 • FAX (626) 458-7637

www.publichealth.lacounty.gov

August 5, 2008



BOARD OF SUPERVISORS

Gloria Molina
First District

Yvonne B. Burke
Second District

Zev Yaroslavsky
Third District

Don Knabe
Fourth District

Michael D. Antonovich
Fifth District

TO: Each Health Deputy

FROM: Wayne K. Sugita, M.P.A., Acting Director
Alcohol and Drug Program Administration

SUBJECT: **FUNDING AUGMENTATION FOR WILSHIRE TREATMENT CENTER,
INCORPORATED, CONTRACT NO. H-701356**

This is to inform you that we plan to amend the County estimated maximum obligation and corresponding maximum allocation for Wilshire Treatment Center, Incorporated using the delegated authority granted by the Board on May 31, 2005 (Board Agenda Synopsis #42). This agency's agreement provides flexibility to adjust funding allocations, and contains provisions that authorize the Director of Public Health or his designee to make such funding changes.

I am recommending this funding increase based on the Sobky v. Smoley court litigation which allowed agencies to request additional funds to cover persons eligible for Drug/Medi-Cal services. The current and proposed funding amounts are as indicated in the following attachments:

Attachment 1 - Description of the services affected by this amendment

Attachment 2 - Agency's current and proposed funding amounts

If you have any questions or need additional information, please let me know.

WKS:fg

Attachments

c: Jonathan E. Fielding, M.D., M.P.H.
Tami Omoto-Frias
Paul H.S. Kim
Jonathan E. Freedman
Wendy Schwartz

Drug/Medi-Cal Services - Description

Narcotic Treatment Program Services (Federal Drug/Medi-Cal)

Narcotic treatment program services provide for the administration of methadone and/or levoalphacetylmethadol, at relatively stable dosage levels for a period in excess of 21 days, as an oral substitute narcotic drug accompanied by ancillary social and medical services for individuals 18 years or older who have a history of two or more years of dependence on heroin or other morphine-like drugs, and two or more failures in alternative treatment programs. Services are provided to Medi-Cal eligible beneficiaries.

WILSHIRE TREATMENT CENTER, INCORPORATED FUNDING INFORMATION

ATTACHMENT 2

Contract #	Fac #	Site Address	SPA	SUP	Modality Description	Modality	Original Board-Approved Amount	Current Funding Allocation FY 2006-07	Proposed Funding Allocation FY 2006-07	Variance
H-701356A	1	11901 Santa Monica Boulevard, Suite 204 Los Angeles CA 90025	5	3	Narcotic Treatment Program Services (Federal Drug/Medi-Cal)	NTP (DMC)	\$44,800	\$220,000	\$222,118	\$2,118